Search clinical trials for: Chloride Channel Agonists

Total 24089 results

Vertex Pharmaceuticals Incorporated

Approved for marketing

Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis

Cystic Fibrosis
University of Louisville
Takeda

Completed

Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit

Constipation

United States
University of Arkansas
Takeda

Terminated

Lubiprostone as a Treatment for Constipation in Parkinson's Disease

Parkinson's Disease | Constipation

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation (KONNECTION)

Cystic Fibrosis

United States, France, Belgium
University of Alabama at Birmingham

Recruiting

Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations

Cystic Fibrosis

United States
University Hospital, Strasbourg, France

Completed

Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor (GLUCORRECTOR)

Cystic Fibrosis Homozygous for Phe 508 Del CFTR | Glucose Intolerance or Newly Diagnosis Diabetes

France
Carmel Medical Center

Completed

Real Life Evaluation of the Multi-organ Effects of Lumacaftor/Ivacaftor on F508del Homozygous Cystic Fibrosis Patients.

Cystic Fibrosis
University of South Alabama
Takeda; Sucampo Pharmaceuticals, Inc.

Completed

Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy

Inflammatory Bowel Disease

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada
Emory University

Completed

The Effectiveness of Lubiprostone in Constipated Diabetics

Diabetes | Constipation

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

Australia, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation

Cystic Fibrosis

Netherlands
Massachusetts General Hospital

Terminated

The Effect of Combination Lumacaftor and Ivacaftor on Markers of Hyperglycemia

Diabetes | Cystic Fibrosis
Asian Institute of Gastroenterology, India

Completed

Comparative Study of Lubiprostone and PEG Preparation Versus Conventional PEG Preparation for Colonoscopy (Lubiprostone)

Colorectal Carcinoma
Vertex Pharmaceuticals Incorporated

Completed

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

Cystic Fibrosis | Advanced Lung Disease

United States
University of Rochester
Takeda

Completed

Lubiprostone in Patients With Multiple Sclerosis Associated Constipation

Multiple Sclerosis | Constipation

United States
Medical University of Vienna

Completed

Mechanisms of Human Heat Perception - Involvement of TRPA1, TRPV1 and TRPM3

Pain

Austria
Helwan University

Completed

Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease

NAFLD

Egypt
Concert Pharmaceuticals

Completed

Study to Evaluate Safety, Tolerability and PK of C-10355 and C-10358 in Healthy Subjects

Healthy

Australia
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States
University of British Columbia

Recruiting

Trikafta Exercise Study in Cystic Fibrosis

Lung Diseases | Cystic Fibrosis

Canada
University of British Columbia

Recruiting

Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF (Can-IMPACT CF)

Cystic Fibrosis

Canada
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI); Vertex Pharmaceuticals Incorporated

Completed

The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor

Chronic Obstructive Pulmonary Disease | Chronic Bronchitis

United States
Jennifer Taylor-Cousar
Cystic Fibrosis Foundation

Recruiting

Impact of Triple Combination CFTR Therapy on Sinus Disease.

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Australia, Denmark, Canada, Sweden
Emory University
National Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis Foundation

Recruiting

Trikafta in Cystic Fibrosis Patients

Cystic Fibrosis

United States
Eloxx Pharmaceuticals, Inc.

Completed

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele

Cystic Fibrosis

Israel, Australia, Germany
Eloxx Pharmaceuticals, Inc.

Completed

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

Cystic Fibrosis

United States, Canada
Braintree Laboratories

Completed

A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

Chronic Idiopathic Constipation

United States
University Hospital, Strasbourg, France

Not yet recruiting

Effect of One Year Elexacaftor-tezacaftor-ivacaftor Treatment (DIATRIM)

Cystic Fibrosis
Augusta University
Takeda Pharmaceuticals North America, Inc.

Terminated

Efficacy of Lubiprostone in Combination With Standard PEG Preparation

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Vertex Pharmaceuticals Incorporated
Moderna, Inc

Recruiting

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, United Kingdom, Australia, Canada
Vertex Pharmaceuticals Incorporated

Completed

Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

United States, Canada
University of South Alabama
Takeda; Sucampo Pharmaceuticals, Inc.

Terminated

Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications

Constipation

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Cystic Fibrosis

United States, Australia, Canada, United Kingdom, Germany, Belgium, Austria, Ireland, Italy, France
Vertex Pharmaceuticals Incorporated

Completed

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

Cystic Fibrosis

United States
Istituto Auxologico Italiano

Recruiting

Mutation-specific Therapy for the Long QT Syndrome (MAST2)

Long QT Syndrome

Italy
Vertex Pharmaceuticals Incorporated

Completed

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada
Concert Pharmaceuticals

Completed

Healthy Volunteer Solid Oral Dose and Multiple Ascending Dose Evaluation of CTP-656

Healthy

Australia
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis

Chronic Rhinosinusitis (Diagnosis)

United States
Vertex Pharmaceuticals Incorporated

Completed

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Denmark, Canada, Australia, Sweden
University of California, San Francisco

Completed

Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients

Cystic Fibrosis

United States
The Alfred

Unknown

CPET in CF Patients With One G551D Mutation Taking VX770

Cystic Fibrosis

Australia
Vertex Pharmaceuticals Incorporated

Completed

Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects

Healthy | Hepatic Impairment

Slovakia, Czech Republic
University of Erlangen-Nürnberg Medical School

Recruiting

Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor

Cystic Fibrosis

Germany
Ruth M. Rothstein CORE Center

Completed

Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy (LAMBCHOP)

HIV

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

Germany
University of Michigan
Takeda Pharmaceuticals North America, Inc.

Completed

Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation

Irritable Bowel Syndrome | Constipation

United States
Brooke Army Medical Center
Takeda

Completed

Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy

Bowel Preparation for Colonoscopy

United States

3

Subscribe